Cumberland Pharmaceuticals and Gloria Pharmaceuticals Announce R&D Investment - - BioPharm International

ADVERTISEMENT

Cumberland Pharmaceuticals and Gloria Pharmaceuticals Announce R&D Investment



Cumberland Pharmaceuticals and Gloria Pharmaceuticals reported a joint R&D initiative. Each company has made a $1 million investment in Cumberland Emerging Technologies (CET), which is majority owned by Cumberland and partners with academic research centers to develop biopharmaceutical technologies. The new funds will be used to accelerate development of CET's pipeline of new product candidates from Vanderbilt University and other regional research centers.

CET was established by Cumberland Pharmaceuticals, Vanderbilt University, and the state of Tennessee to support the development of biopharmaceutical product candidates. Gloria will have the first opportunity to negotiate a license to CET products for China, and Cumberland will retain access to CET's product rights for the rest of the world.

Source: Cumberland Pharmaceuticals

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Suppliers Seek to Boost Single-Use Technology
August 21, 2014
Bristol-Myers Squibb and Celgene Collaborate on Immunotherapy and Chemotherapy Combination Regimen
August 20, 2014
USP Center in Ghana Receives International Lab Accreditation
August 15, 2014
USP Awards Analytical Research
August 15, 2014
FDA Warns about Fraudulent Ebola Treatments
August 15, 2014
Author Guidelines

Click here